Form 4: Nurix Therapeutics CFO Hans van Houte Sells 20,000 Shares

Nurix Therapeutics' Chief Financial Officer, Hans van Houte, sold 20,000 shares of common stock on August 26, 2024, at a weighted average price of $25.2185 per share.

Summary

• On August 26, 2024, Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, Inc., sold 20,000 shares of the company's common stock.
• The sale was executed at a weighted average price of $25.2185 per share.
• The price range for the shares sold was between $25.00 and $25.58.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
• Following the transaction, van Houte directly owns 31,002 shares of Nurix Therapeutics.
• Daniel Burbach, as Attorney-in-Fact for Hans van Houte, signed the form.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by a company executive. It doesn't inherently convey positive or negative sentiment, but the market's reaction will depend on its interpretation of the sale.

Industry Context

Insider sales are common and can be for various reasons, including diversification or personal financial planning. However, significant insider selling can sometimes be viewed negatively by investors if it suggests a lack of confidence in the company's future prospects.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, such as Nurix Therapeutics, to have pre-arranged trading plans like Rule 10b5-1 to sell shares periodically.
• Comparing the volume and frequency of insider sales at Nurix to similar biotech companies like Arvinas or Relay Therapeutics could provide context on whether this activity is typical.
• The weighted average sale price of $25.2185 can be benchmarked against the average trading volume and price volatility of NRIX stock over the past few months to assess the impact of this sale.

Stakeholder Impact

• The sale of shares by a high-ranking executive could potentially influence investor sentiment, depending on the size of the sale and the context.
• Shareholders may interpret the sale as a lack of confidence in the company's future prospects, although it could also be due to personal financial planning.

Key Dates